Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases

BT-061 in clinical development for the treatment of RA and psoriasis

24-Jun-2011 - Germany

Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study its potential use in other immune-related diseases.

CD4 is expressed on T-cells and is involved in T-cell mediated modulation of immune responses. BT-061 is a humanized monoclonal antibody that works by activating the body's T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive immune reactions. Unlike other anti-CD4 antibodies that have been in development, BT-061 does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses.

Under the terms of the agreement, Abbott and Biotest will co-promote BT-061 in the five major European markets (Germany, France, United Kingdom, Italy and Spain) and Abbott will have exclusive global rights to commercialize BT-061 outside those countries. Biotest will receive an upfront fee of $85MM. Pending achievement of certain development, regulatory, commercial and sales-based milestones, Biotest would be eligible to receive additional milestone payments from Abbott, potentially amounting to a total of $395MM, and royalties. Biotest will be responsible for manufacturing the initial clinical supply of BT-061 and the companies will share responsibility for commercial production.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances